We observed that CD155 and CD112 were expressed at higher levels than MICA, MICB, ULBP1-2-5-6, PDL-1, and B7-H6 on all the prostate cancer cells (Figure 2(b) and 2(c), ∗∗∗p < 0.001). Here, MICB is linked to prostate carcinoma.